Dianthus Therapeutics, Inc.
DNTH
Classifica tra le azioni
#3914
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in... Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Prezzo delle azioni
$75.21
Capitalizzazione di mercato
$4.21B
Variazione (1 giorno)
4.33%
Variazione (1 anno)
110.98%
Paese
US
Scambia Dianthus Therapeutics, Inc. (DNTH)
Categoria
Healthcare
Rapporto P/B per Dianthus Therapeutics, Inc. (DNTH)
Rapporto P/B al October 2026 TTM: 3.57
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Dianthus Therapeutics, Inc., il rapporto P/B attuale (TTM) è 3.57. Alla fine del 2023, era pari a 0.32.
Storico del rapporto P/B per Dianthus Therapeutics, Inc. da 2016 a 2026
Rapporto P/B alla fine di ogni anno
| Anno | Rapporto P/B | Cambia |
|---|---|---|
| 2026 (TTM) | 3.57 | 73.49% |
| 2024 | 2.06 | 549.15% |
| 2023 | 0.32 | -159.46% |
| 2022 | -0.53 | -137.87% |
| 2021 | 1.41 | -41.09% |
| 2020 | 2.39 | -39.79% |
| 2019 | 3.97 | 204.85% |
| 2018 | 1.30 | -87.23% |
| 2017 | 10.21 | -82.03% |
| 2016 | 56.80 | 0.00% |
Rapporto P/B per aziende simili o concorrenti
| Azienda | Rapporto P/B | Differenza del rapporto P/B | Il paese |
|---|---|---|---|
| 6.251 | 74.91% |
US
|
|
| 13.2547 | 270.87% |
US
|
|
| 4.208 | 17.74% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | 72.99% |
NL
|
